CrystalO Biopharma Signs Collaboration and Licensing Deal with Almirall for AI-Driven Skin Disease Drug Discovery, Valued Up to €254.5 Million

August 17, 2026

Insight, China’s Pharmaceutical Industry China

Overview

CrystalO Biopharma has signed a collaboration and licensing agreement with Almirall, a global biopharmaceutical company, to develop innovative drug candidates for skin diseases. The deal is potentially worth up to €254.5 million in upfront, milestone, and royalty payments. This agreement validates CrystalO’s AI- and structural biology-driven drug discovery platform and strengthens Almirall’s pipeline in medical dermatology.

In Depth

Key Findings

CrystalO Biopharma has entered into a collaboration and licensing agreement with Almirall, a global biopharmaceutical company, to jointly develop innovative drug candidates for skin diseases, leveraging CrystalO’s AI-driven drug discovery platform. This agreement could be worth up to €254.5 million (approximately $270 million) in upfront, development and sales milestones, and royalty payments. This substantial deal strongly validates CrystalO’s powerful drug discovery platform, which integrates AI with structural biology.

Technical / Clinical Details

CrystalO Biopharma’s platform combines artificial intelligence with cutting-edge structural biology techniques to more accurately identify disease-causing targets and design high-affinity, high-selectivity drug candidates that modulate specific disease pathways. Skin diseases present diverse pathologies, and existing treatments often have insufficient efficacy or significant side effects. AI processes vast amounts of biological data, chemical structure data, and clinical data to generate new therapeutic hypotheses and rapidly design optimal molecular structures. This enables Almirall to strengthen its pipeline in medical dermatology, including conditions like psoriasis, atopic dermatitis, and acne vulgaris, aiming to provide patients with innovative treatment options.

Background & Context

The drug discovery process is challenged by its time-consuming, costly nature, and low success rates, particularly for complex diseases. The integration of AI is expected to be a game-changer in overcoming these inefficiencies. AI-driven drug discovery companies like CrystalO are accelerating the transformation of the pharmaceutical industry by enabling the discovery and optimization of drug candidates at speeds and precision impossible with traditional research methods. The partnership between a major pharmaceutical company like Almirall and an AI startup signifies the widespread recognition of AI’s strategic value in drug discovery.

Strategic Significance & Outlook

The collaboration between Almirall and CrystalO Biopharma demonstrates the potential for AI-driven drug discovery to yield tangible results in the dermatological field. Through this agreement, both companies can accelerate the development of new skin disease treatments, potentially offering innovative solutions to patients with high unmet needs. The success of CrystalO’s platform will show that the combination of AI and structural biology is a powerful tool for streamlining drug discovery processes in other disease areas as well. In the future, such AI-driven partnerships are expected to become a standard approach in drug development, further driving innovation across the healthcare sector.

Source: https://flcube.com/?p=72249

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.